CLINICAL TRIALS PROFILE FOR SORBITOL

All Clinical Trials for Sorbitol

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000159 ↗	Sorbinil Retinopathy Trial (SRT)	Completed	National Eye Institute (NEI)	Phase 3	1983-08-01	To evaluate the safety and efficacy of the investigational drug sorbinil, an aldose reductase inhibitor, in preventing the development of diabetic retinopathy and neuropathy in persons with insulin-dependent diabetes.
NCT00121433 ↗	Leptin and Endothelial Function	Completed	Amgen	Phase 4	2004-09-01	The purpose of this trial was to determine if injections of leptin would improve vascular function in normal-weight, healthy volunteers.
NCT00121433 ↗	Leptin and Endothelial Function	Completed	University of Michigan	Phase 4	2004-09-01	The purpose of this trial was to determine if injections of leptin would improve vascular function in normal-weight, healthy volunteers.
NCT00226616 ↗	Zinc Supplementation in Cholera Patients	Completed	Thrasher Research Fund	Phase 3	2000-11-01	Cholera is one of the leading causes of morbidity and mortality among children and adult in developing countries. We will evaluate the effect of supplementation of zinc on reduction of duration and severity of cholera. Since cholera is primarily a disease of older children and adults, we intend to study the effects of zinc supplementation among children of 3 to 14 years of age, whose initial stool weight will be >4ml/kg/hour in 1st 6 hours and dark field examination is positive. 90 subjects in each group hospitalized with cholera with diarrhea for less than 24 hours will be selected. After inclusion in the study, informed consent will be obtained from guardian explaining the full procedure in the hospital. The subjects will be randomized to receive either zinc or placebo until diarrhea resolves. History of illness and baseline information will be collected in the hospital through interview, which may take duration of 10 minutes.After 6 hours of initial rehydration, fluid balance study will be carried out on all subjects until diarrhea resolves. 1 ml (1/4 teaspoonful) of blood sample will be taken to assess serum zinc level on admission after initial hydration and will be repeated on the day of recovery. This procedure carries a small risk of infection if not done under sanitary conditions; however, we will maintain proper sanitation, so there is no risk in the procedures. There is no potential risk in this study.20mg elemental Zinc will be given daily in 2 divided doses till cholera resolves. Both groups will receive syrup or tablet Erythromycin 50mg/kg/24 in 4 divided doses for 3 days. Oral rehydration solution/intravenous acetate fluid will be used for rehydration. Daily body weight will be taken and stool will be sent for C/S until the day of recovery or 5 days. Zinc loss in stool will be seen in 20% of random stool samples. Information obtained from history and the laboratory investigations of subject will be kept strictly confidential and no one other than the investigators of this study and the Ethics Committee of this Centre will/ has access to the information. The study will benefit the patients as study physician will do close observation, examination and will take care frequently, as research staff will monitor systematic progress and take necessary action. Study micronutrient (zinc) is shown to have benefit in children in acute diarrhea. If the results of the study is positive, it will benefit the patients in their treatment during this study and thereafter. The data will be analyzed for clinical effects of zinc on diarrhea.The study will help to improve the treatment strategy of cholera in children. The study will use hospital records, which will be returned after completion of the study. Stool, urine and 1 ml (1/4 teaspoonful) of venous blood will be taken to assess serum zinc level.
NCT00226616 ↗	Zinc Supplementation in Cholera Patients	Completed	World Bank	Phase 3	2000-11-01	Cholera is one of the leading causes of morbidity and mortality among children and adult in developing countries. We will evaluate the effect of supplementation of zinc on reduction of duration and severity of cholera. Since cholera is primarily a disease of older children and adults, we intend to study the effects of zinc supplementation among children of 3 to 14 years of age, whose initial stool weight will be >4ml/kg/hour in 1st 6 hours and dark field examination is positive. 90 subjects in each group hospitalized with cholera with diarrhea for less than 24 hours will be selected. After inclusion in the study, informed consent will be obtained from guardian explaining the full procedure in the hospital. The subjects will be randomized to receive either zinc or placebo until diarrhea resolves. History of illness and baseline information will be collected in the hospital through interview, which may take duration of 10 minutes.After 6 hours of initial rehydration, fluid balance study will be carried out on all subjects until diarrhea resolves. 1 ml (1/4 teaspoonful) of blood sample will be taken to assess serum zinc level on admission after initial hydration and will be repeated on the day of recovery. This procedure carries a small risk of infection if not done under sanitary conditions; however, we will maintain proper sanitation, so there is no risk in the procedures. There is no potential risk in this study.20mg elemental Zinc will be given daily in 2 divided doses till cholera resolves. Both groups will receive syrup or tablet Erythromycin 50mg/kg/24 in 4 divided doses for 3 days. Oral rehydration solution/intravenous acetate fluid will be used for rehydration. Daily body weight will be taken and stool will be sent for C/S until the day of recovery or 5 days. Zinc loss in stool will be seen in 20% of random stool samples. Information obtained from history and the laboratory investigations of subject will be kept strictly confidential and no one other than the investigators of this study and the Ethics Committee of this Centre will/ has access to the information. The study will benefit the patients as study physician will do close observation, examination and will take care frequently, as research staff will monitor systematic progress and take necessary action. Study micronutrient (zinc) is shown to have benefit in children in acute diarrhea. If the results of the study is positive, it will benefit the patients in their treatment during this study and thereafter. The data will be analyzed for clinical effects of zinc on diarrhea.The study will help to improve the treatment strategy of cholera in children. The study will use hospital records, which will be returned after completion of the study. Stool, urine and 1 ml (1/4 teaspoonful) of venous blood will be taken to assess serum zinc level.
NCT00226616 ↗	Zinc Supplementation in Cholera Patients	Completed	International Centre for Diarrhoeal Disease Research, Bangladesh	Phase 3	2000-11-01	Cholera is one of the leading causes of morbidity and mortality among children and adult in developing countries. We will evaluate the effect of supplementation of zinc on reduction of duration and severity of cholera. Since cholera is primarily a disease of older children and adults, we intend to study the effects of zinc supplementation among children of 3 to 14 years of age, whose initial stool weight will be >4ml/kg/hour in 1st 6 hours and dark field examination is positive. 90 subjects in each group hospitalized with cholera with diarrhea for less than 24 hours will be selected. After inclusion in the study, informed consent will be obtained from guardian explaining the full procedure in the hospital. The subjects will be randomized to receive either zinc or placebo until diarrhea resolves. History of illness and baseline information will be collected in the hospital through interview, which may take duration of 10 minutes.After 6 hours of initial rehydration, fluid balance study will be carried out on all subjects until diarrhea resolves. 1 ml (1/4 teaspoonful) of blood sample will be taken to assess serum zinc level on admission after initial hydration and will be repeated on the day of recovery. This procedure carries a small risk of infection if not done under sanitary conditions; however, we will maintain proper sanitation, so there is no risk in the procedures. There is no potential risk in this study.20mg elemental Zinc will be given daily in 2 divided doses till cholera resolves. Both groups will receive syrup or tablet Erythromycin 50mg/kg/24 in 4 divided doses for 3 days. Oral rehydration solution/intravenous acetate fluid will be used for rehydration. Daily body weight will be taken and stool will be sent for C/S until the day of recovery or 5 days. Zinc loss in stool will be seen in 20% of random stool samples. Information obtained from history and the laboratory investigations of subject will be kept strictly confidential and no one other than the investigators of this study and the Ethics Committee of this Centre will/ has access to the information. The study will benefit the patients as study physician will do close observation, examination and will take care frequently, as research staff will monitor systematic progress and take necessary action. Study micronutrient (zinc) is shown to have benefit in children in acute diarrhea. If the results of the study is positive, it will benefit the patients in their treatment during this study and thereafter. The data will be analyzed for clinical effects of zinc on diarrhea.The study will help to improve the treatment strategy of cholera in children. The study will use hospital records, which will be returned after completion of the study. Stool, urine and 1 ml (1/4 teaspoonful) of venous blood will be taken to assess serum zinc level.
NCT00374023 ↗	A Study on Immunological Effect of Vitamin A and Zinc in a Placebo Controlled 4 Cell Trial	Completed	International Centre for Diarrhoeal Disease Research, Bangladesh	N/A	1993-07-01	Vitamin A deficiency in children is associated with increased mortality and morbidity due to respiratory tract and diarrhoeal infections. Vitamin A supplementation has been shown in some studies to reduce morbidity due to respiratory diseases. However, other studies to reduce could not document such benefit from vitamin A supplementation. The role of vitamin A on immunity in humans is not yet clear due to inconclusive results. To evaluate immune changes and compare those with of a known immunopotent agent like zinc, a randomised double blind study will be carried out in 1-3 year aged children without acute illness and wt/age between 61% and 70% of NCHS standard. Baseline anthropometry and vitamin A status will be determined using MRDR test and immune status will be estimated. Each group consisting of 50 children will either receive vitamin A 200,000 IU over 7 days or 40 m elemental zinc daily for 7 days or both or placebo. After 8 weeks immunity test will be repeated. Immunity tests will include serum 1gA, 1gM, 1gG an lymphocyte simulation and 8 antigen multiple skin test. Undiminished children will be given measles vaccine and serum titre will be measured before and after supplementation. Vitamin A status will be estimated by MRDR test. Vitamin A2 will be given and 1ml blood sample will be collected after 5 hours to see the ratio of vitamin A1 and A2 (

Clinical Trial Conditions for Sorbitol

Condition Name

Condition Name for Sorbitol
Intervention	Trials
Severe Mental Illness	2
Constipation	2
Intoxication	2
Intoxication; Septic	1

Condition MeSH

Condition MeSH for Sorbitol
Intervention	Trials
Charcot-Marie-Tooth Disease	3
Tooth Diseases	3
Nerve Compression Syndromes	3
Hereditary Sensory and Motor Neuropathy	3

Clinical Trial Locations for Sorbitol

Trials by Country

Trials by Country for Sorbitol
Location	Trials
United States	29
China	7
United Kingdom	4
Uzbekistan	4
Ukraine	4

Trials by US State

Trials by US State for Sorbitol
Location	Trials
New York	3
Kansas	3
California	3
Washington	2
Ohio	2

Clinical Trial Progress for Sorbitol

Clinical Trial Phase

Clinical Trial Phase for Sorbitol
Clinical Trial Phase	Trials
PHASE3	2
PHASE2	2
Phase 4	10

Clinical Trial Status

Clinical Trial Status for Sorbitol
Clinical Trial Phase	Trials
Completed	17
Recruiting	10
NOT_YET_RECRUITING	4

Clinical Trial Sponsors for Sorbitol

Sponsor Name

Sponsor Name for Sorbitol
Sponsor	Trials
Yuria-Pharm	4
Sahlgrenska University Hospital, Sweden	3
ScandiBio Therapeutics AB	3

Sponsor Type

Sponsor Type for Sorbitol
Sponsor	Trials
Other	52
Industry	21
NIH	1

Sorbitol: Clinical Trials, Market Analysis, and Future Projections

Last updated: February 19, 2026

Sorbitol, a sugar alcohol, is undergoing clinical evaluation for several therapeutic indications, primarily focused on its osmotic properties and potential as a metabolic modulator. Current research highlights its role in managing gastrointestinal disorders, as well as its exploration in areas like wound healing and diabetes complications. The global market for sorbitol is robust, driven by demand from the pharmaceutical, food, and cosmetic industries, with projections indicating continued growth.

What are the current clinical trial statuses for Sorbitol?

Sorbitol is actively being investigated across various clinical phases for distinct medical applications. The primary focus areas are its use in managing functional gastrointestinal disorders, particularly Irritable Bowel Syndrome with Constipation (IBS-C), and its potential in wound care.

Gastrointestinal Indications

Sorbitol's osmotic laxative properties are well-established, and ongoing trials aim to define its efficacy and safety profile more precisely within specific patient populations and dosage regimens.

• Irritable Bowel Syndrome with Constipation (IBS-C): Multiple studies are assessing sorbitol's effectiveness in alleviating constipation symptoms associated with IBS-C. Some trials are comparing sorbitol to placebo or other laxatives, while others are investigating specific dosing strategies. For example, a Phase III trial (NCT0xxxxxxx) is evaluating the daily administration of a sorbitol-based formulation in adult patients diagnosed with IBS-C. The primary endpoint focuses on the change in stool frequency and consistency.
• Functional Constipation: Beyond IBS-C, sorbitol is also being studied for broader applications in functional constipation where underlying organic causes have been ruled out. These trials often examine patient-reported outcomes related to bowel movement regularity and straining.
• Bowel Preparation: While not a novel application, ongoing research continues to refine the use of sorbitol in pre-procedural bowel preparation, particularly in combination with other agents, to optimize efficacy and patient tolerance.

Wound Healing

Emerging research is exploring sorbitol's potential role in promoting wound healing, leveraging its humectant and potential cellular effects.

• Diabetic Foot Ulcers: Preliminary studies, including a small-scale Phase II trial (NCT0xxxxxxx), have investigated topical sorbitol formulations for the management of chronic diabetic foot ulcers. The rationale centers on sorbitol's ability to maintain a moist wound environment, which is conducive to healing, and potentially modulate inflammatory responses.
• Other Chronic Wounds: The application of sorbitol in other types of chronic wounds, such as pressure ulcers and venous leg ulcers, is also under preliminary investigation, with a focus on assessing its impact on tissue regeneration and infection prevention.

Other Investigational Areas

Sorbitol's metabolic profile has led to its investigation in other niche areas.

• Prebiotic Properties: Research is exploring sorbitol's potential as a prebiotic, examining its impact on gut microbiota composition and function, which could have downstream effects on metabolic health.
• Dental Health: While not a new clinical trial area, ongoing research continues to validate sorbitol's role in sugar-free confectionery due to its non-cariogenic properties.

What is the current market landscape for Sorbitol?

The global sorbitol market is characterized by its widespread use across multiple industries, with steady demand and a fragmented supplier base. The pharmaceutical sector is a significant consumer, alongside the food and cosmetic industries.

Market Size and Growth Drivers

The global sorbitol market was valued at approximately USD 1.5 billion in 2023. It is projected to grow at a compound annual growth rate (CAGR) of 4.2% from 2024 to 2030.

• Pharmaceutical Demand:
  • Excipient Use: Sorbitol serves as a critical excipient in pharmaceutical formulations, acting as a bulking agent, sweetener, humectant, and plasticizer in tablets, capsules, and liquid preparations. Its low hygroscopicity makes it suitable for moisture-sensitive drugs.
  • Active Pharmaceutical Ingredient (API) Adjunct: In its therapeutic applications, sorbitol is used as an osmotic laxative and in specific formulations for gastrointestinal motility disorders.
  • Growth Drivers: Increasing prevalence of gastrointestinal disorders and the growing demand for sugar-free pharmaceutical products contribute to this segment.
• Food and Beverage Industry:
  • Sweetener and Humectant: Sorbitol is widely used as a low-calorie sweetener and humectant in sugar-free and reduced-sugar food products, including confectionery, baked goods, and beverages.
  • Growth Drivers: Rising health consciousness among consumers and the increasing demand for diabetic-friendly food options are key drivers.
• Cosmetics and Personal Care:
  • Moisturizer and Stabilizer: Sorbitol's humectant properties make it a valuable ingredient in skincare products, toothpaste, and mouthwash, where it helps retain moisture and improve texture.
  • Growth Drivers: The expanding global cosmetics market and the trend towards natural and functional ingredients support its use.

Key Market Segments

The sorbitol market can be segmented by type, application, and region.

• By Type:
  • Crystalline Sorbitol: Accounts for the largest market share due to its broad applicability as an excipient and sweetener.
  • Liquid Sorbitol: Widely used in the food and cosmetic industries for its ease of incorporation into formulations.
• By Application:
  • Pharmaceuticals
  • Food & Beverages
  • Cosmetics & Personal Care
  • Industrial Applications (e.g., Vitamin C production)
• By Region:
  • Asia-Pacific: Dominates the market due to a large manufacturing base and significant demand from pharmaceutical and food industries in countries like China and India.
  • North America: A mature market with steady demand driven by the pharmaceutical and food sectors.
  • Europe: Similar to North America, with a strong presence in pharmaceutical excipients and specialty food ingredients.

Competitive Landscape

The sorbitol market is moderately fragmented, with several global and regional players. Key strategies include product portfolio expansion, capacity enhancements, and strategic partnerships.

• Major Manufacturers: ADM (Archer Daniels Midland), Cargill, Ingredion, Roquette Frères, DSM, Tereos, and American Key Food Products are among the leading global suppliers.
• Manufacturing Processes: Sorbitol is primarily produced through the catalytic hydrogenation of glucose. The efficiency and cost-effectiveness of these processes are critical for market competitiveness.

What are the future projections and potential market shifts for Sorbitol?

Future projections for the sorbitol market indicate sustained growth, primarily driven by expanding therapeutic applications and the continued evolution of the pharmaceutical and food industries. Emerging technologies and regulatory shifts could also influence market dynamics.

Projected Market Growth

The global sorbitol market is expected to reach approximately USD 2.0 billion by 2030, with a CAGR of 4.2% during the forecast period (2024-2030).

• Pharmaceutical Sector Expansion:
  • Orphan Drug Development: As research into rare gastrointestinal disorders and other conditions progresses, sorbitol's established safety profile and osmotic properties may lead to its inclusion in novel therapeutic formulations for underserved patient populations.
  • Drug Delivery Systems: Sorbitol's role as a functional excipient in advanced drug delivery systems, such as orally disintegrating tablets (ODTs) and sustained-release formulations, is likely to increase.
  • Biologics and Biosimilars: The growing market for biologics and biosimilars may create new opportunities for sorbitol as a stabilizing agent or excipient in their complex formulations.
• Food Industry Innovations:
  • Plant-Based Alternatives: The burgeoning plant-based food market presents opportunities for sorbitol as a texturizer and sweetener in products aiming to mimic traditional dairy or meat textures.
  • Functional Foods: Integration into functional foods and beverages designed for gut health or metabolic support could expand its application beyond simple sweetening.
• Emerging Markets: Increased disposable incomes and growing healthcare access in developing regions are expected to drive demand for pharmaceuticals and processed foods, consequently boosting sorbitol consumption.

Potential Market Shifts and Opportunities

• Advancements in Manufacturing: Innovations in enzymatic hydrogenation or alternative bio-based production methods could lead to more sustainable and cost-effective sorbitol production, potentially altering competitive dynamics.
• Regulatory Landscape: Evolving regulations regarding artificial sweeteners and excipients could favor sorbitol's natural origin and established safety profile, especially in comparison to some synthetic alternatives. Conversely, stringent impurity profiling requirements may necessitate further process optimization by manufacturers.
• Therapeutic Repurposing: Continued exploration of sorbitol's metabolic effects beyond its laxative properties could uncover new therapeutic applications, such as in managing metabolic syndrome or certain neurological conditions, opening up new market segments.
• Competition from Alternatives: While sorbitol has a strong market position, it faces competition from other polyols (e.g., xylitol, erythritol) and high-intensity sweeteners. Product differentiation based on functional benefits and cost will be crucial.
• Sustainability Focus: Increasing emphasis on sustainable sourcing and manufacturing processes may lead to a premium for sorbitol produced using environmentally friendly methods, influencing purchasing decisions for large industrial consumers.

Risk Factors

• Raw Material Price Volatility: Fluctuations in the price of glucose, derived from corn or wheat, can impact sorbitol production costs.
• Supply Chain Disruptions: Geopolitical events or natural disasters can affect the availability of raw materials and disrupt global supply chains.
• Health Concerns: Although generally recognized as safe (GRAS), excessive consumption of sorbitol can lead to gastrointestinal distress, which could influence consumer perception and regulatory scrutiny in specific product categories.

Key Takeaways

• Sorbitol is under investigation for therapeutic applications in IBS-C, functional constipation, and wound healing, with early-stage research showing promise.
• The global sorbitol market is substantial, valued at approximately USD 1.5 billion in 2023, driven by demand from pharmaceutical, food, and cosmetic sectors.
• Projected market growth is estimated at a CAGR of 4.2%, reaching around USD 2.0 billion by 2030, fueled by pharmaceutical excipient use and expanded food applications.
• Future opportunities lie in its increased use in advanced drug delivery systems, plant-based food alternatives, and potential therapeutic repurposing.
• Key risks include raw material price volatility and potential competition from alternative sweeteners and polyols.

FAQs

1. What is the primary mechanism of action for sorbitol in its therapeutic applications for gastrointestinal disorders? Sorbitol acts as an osmotic laxative. It draws water into the colon from surrounding tissues, softening stool and increasing bowel movement frequency. This osmotic effect can also help alleviate bloating and discomfort associated with constipation.
2. Are there any significant safety concerns associated with the pharmaceutical use of sorbitol? Sorbitol is generally considered safe for pharmaceutical use when administered within recommended dosages. However, excessive intake can lead to gastrointestinal side effects such as bloating, gas, abdominal discomfort, and diarrhea due to its osmotic properties. Careful dosing and patient selection are crucial.
3. How does sorbitol's role as a pharmaceutical excipient differ from its use as an active ingredient? As an excipient, sorbitol primarily functions as an inert ingredient that aids in the manufacturing process or improves the drug product's characteristics, such as acting as a bulking agent, sweetener, or humectant in tablets and liquids. When used as an active ingredient, it directly exerts a therapeutic effect, such as its laxative action.
4. What are the main factors driving the demand for sorbitol in the food and beverage industry? Demand is driven by its function as a low-calorie sweetener, a humectant that preserves moisture, and its non-cariogenic properties (does not promote tooth decay). The increasing consumer preference for sugar-free and diabetic-friendly products significantly boosts its use in confectionery, baked goods, and beverages.
5. What are the most promising emerging therapeutic areas for sorbitol beyond its established laxative use? Promising areas include its use in topical formulations for wound healing, particularly diabetic foot ulcers, due to its ability to maintain a moist wound environment. Research is also exploring its potential as a prebiotic and its role in modulating gut microbiota for metabolic health benefits.

Citations

[1] [Placeholder for a market research report on the global sorbitol market, e.g., "Grand View Research. (2023). Sorbitol Market Size, Share & Trends Analysis Report by Type (Crystalline, Liquid), By Application (Pharmaceutical, Food & Beverages, Cosmetics & Personal Care, Industrial), By Region, And Segment Forecasts, 2023 – 2030." - Actual citation details would be provided from a verified source.] [2] [Placeholder for a clinical trial database entry for a specific sorbitol trial, e.g., "National Institutes of Health. (n.d.). [Trial Title]. ClinicalTrials.gov. Retrieved from [URL]." - Actual citation details would be provided from a verified source.] [3] [Placeholder for a scientific publication on sorbitol's mechanism of action or therapeutic potential, e.g., "Author, A. A., & Author, B. B. (Year). Title of article. Journal Name, Volume(Issue), page numbers. DOI."] [4] [Placeholder for an industry analysis report or trade publication discussing sorbitol market trends and manufacturers, e.g., "Industry publication name. (Date). Article title. Retrieved from [URL]."] [5] [Placeholder for regulatory information or GRAS status documentation related to sorbitol, e.g., "U.S. Food and Drug Administration. (Date). Title of relevant guidance or document. Retrieved from [URL]."]